ANNALS OF ONCOLOGY Journal
Overview
publication venue for
- Correlation of safety and efficacy in atezolizumab therapy across indications 2023
- Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity 2023
- Patient-reported outcomes (PROs) in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial 2023
- Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study 2023
- Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma 2022
- Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP) 2022
- A phase II (ph2), randomized study of magrolimab with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC) 2022
- High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC) 2022
- Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET plus colorectal carcinoma as a unique molecular subset of CRC 2022
- Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study 2022
- Efficacy and safety of poziotinib in treatment-naive HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4 2022
- Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS >= 1% (LEAP-007): A phase III, randomized, double-blind study 2021
- Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer 2021
- Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy 2021
- DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial 2021
- Efficacy and safety of poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4) 2021
- Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors 2021
- Final efficacy results from IMpower132: First-line atezolizumab plus chemotherapy in patients with stage IV non-squamous NSCLC 2020
- IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations 2020
- IMpower150: Updated efficacy analysis in patients with EGFR mutations 2020
- KRAS mutant epithelial ovarian carcinomas (EOC) represent distinct genomic genotypes 2020
- Phase II trial of oncolytic vaccinia virus primed immunochemotherapy in platinum-resistant/refractory ovarian cancer (PRROC) (NCT02759588) 2020
- Phase III confirmatory efficacy and safety study of proposed bevacizumab biosimilar (MYL-1402O) compared with avastin, in the first-line treatment of patients with stage IV non-squamous non-small cell lung cancer (nsNSCLC) 2020
- SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer 2020
- Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study 2020
- Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins) 2020
- ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations 2020
- Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment 2019
- Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC) 2019
- SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer 2019
- IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations 2019
- IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations 2018
- IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin plus nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC 2018
- IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel in 1L advanced squamous NSCLC 2018
- IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) plus chemotherapy (chemo) +/- bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC 2018
- Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC) 2018
- Real-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK plus non-small cell lung cancer (NSCLC) 2018
- Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3 2018
- nab-paclitaxel plus carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND. sqm study 2018
- Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer 2018
- Primary PFS and safety analyses of a randomized phase III study of carboplatin plus paclitaxel plus /- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150) 2017
- ARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC) 2017
- Blood first line ready screening trial ( B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic 2017
- Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC) 2017
- Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK plus lung cancer: Updated results from PROFILE 1014 2017
- PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC 2017
- nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial 2017
- Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. 28:354-361. 2017
- A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC 2016
- Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. 27:1573-1579. 2016
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer (vol 26, pg 1923, 2015) 2016
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer (vol 26, pg 1923, 2015) 2015
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer(aEuro). 26:1923-1929. 2015
- FIRST-LINE CRIZOTINIB VS PEMETREXED plus CISPLATIN/CARBOPLATIN IN ASIAN PATIENTS WITH ADVANCED ALK plus NSCLC IN PROFILE 1014 2014
- Plasma methionine, choline, betaine, and dimethylglycine in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). 25:1609-1615. 2014
- A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). 24:2382-2389. 2013
- Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. 24:2390-2396. 2013
- Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. 23:1723-1729. 2012
- A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF HEDGEHOG (HH) PATHWAY INHIBITOR GDC-0449 AS MAINTENANCE THERAPY IN PATIENTS WITH OVARIAN CANCER IN 2(ND) OR 3(RD) COMPLETE REMISSION (CR) 2010
- THE SAFETY OF NERATINIB (HKI-272) IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH SOLID TUMORS: A PHASE 1/2 STUDY 2010
- A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. 21:540-547. 2010
- A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). 20:1068-1073. 2009
- PHASE (PH) I/II STUDY OF THE HISTONE DEACETYLASE INHIBITOR BELINOSTAT (BEL) IN COMBINATION WITH CARBOPLATIN (CA) AND PACLITAXEL (P) IN ADVANCED SOLID TUMORS (PH I) AND RELAPSED OVARIAN CANCER (PH II) 2008
- Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. 19:265-268. 2008
- Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. 18:249-255. 2007
- Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. 17:860-865. 2006
- A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. 17:104-109. 2006
- Randomized phase III trial comparing cisplatin-etoposide to carhoplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. 16:1069-1075. 2005
- Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. 15:1033-1041. 2004
Research
category
- ONCOLOGY Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 0923-7534
Electronic International Standard Serial Number (EISSN)
- 1569-8041
Other
journal abbreviation
- ANN ONCOL